Tolerability and efficacy of anti-influenza vaccination alone and associated with antipneumococcal vaccination in an elderly ambulatory population and adherence to the vaccination campaign

Journal of Preventive Medicine and Hygiene

Volumn 45, Issue 3, 2004, Pages 45-50

  Consonni, S ^a   Sandrini, C ^a   Segato, E ^a   Perucchini, E ^a   Bergamaschini, Luigi ^a   Vergani, C ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Anti influenza vaccination; Anti pneumococcal vaccination; Elderly

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; MUCOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PNEUMOCOCCUS VACCINE;

AGED; AMBULATORY CARE; ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GERIATRIC CARE; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INTELLIGENCE; MAJOR CLINICAL STUDY; MALE; MOOD; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; SIDE EFFECT; STREPTOCOCCUS INFECTION;

EID: 17444366588     PISSN: 11212233     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Allsup SJ, Gosney M, Regan M, Haycox A, Fear S, Johnstone FC. Side effects of influenza vaccination in healthy older people: a randomised single blind placebo controlled trial. Gerontology 2001;47:311-4.
2. Austrian R, Douglas RM, Schiffman G, Coetzee AM, Koornhof HJ, Hayden-Smith S, et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976;89:184-9.
3. Barry DW, Mayner RE, Hochstein HD, Dunlap RC, Rastogi SC, Hannah JE, et al. Comparative trial of influenza vaccine. Adverse reactions in children and adults. Am J Epidemiol 1976;104:47-59.
4. Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR. Polysaccharide pneumococcal vaccine efficacy: an evaluation of current recommendations. JAMA 1993;270:1826-31.
5. Christenson B, Lundberg P, Hedlund J, Ortqvist A. Effects of a large-scale intervention with influenza and 23-valent pneumococcal vaccines in adults aged 65 years or older: a prospective study. Lancet 2001;357:1008-11.
6. Christenson B, Lundeberg P. Comparison between cohorts vaccinated and unvaccinated against influenza and pneumococcal infection. Epidemiol Infect Dec 2002;129:515-24.
7. Conne P, Gauthey L, Vernet P, Althaus B, Que JU, Finkel B, et al. Immunogenicity of trivalent subunit versus virosome-formulated influenza vaccines in geriatric patients. Vaccine 1997;15(15):1675-9.
8. Couch RB. Prevention and treatment of influenza. NEJM 2002;343:1778-87.
9. Cox NJ, Subbarao K. Influenza. The Lancet 1999;354:1277-82.
10. Farr BM, Johnston BL, Cobb DK, Fisch MJ, Germanson TP, Adal KA, et al. Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study. Arch Intern Med 1995;155: 2336-40.
11. Fedson D. Pneumococcal vaccination for older adults: the first 20 years. Drugs&Aging 1999;15:21-30.
12. Fedson D, Henrichsen J, Makela PH, Austrian R. Immunization of elderly people with polyvalent pneumococcal vaccine. Infection 1989;17:437-41.
13. Fiebach N, Beckett W. Prevention of respiratory infections in adults. Influenza and pneumococcal vaccines. Archives of Internal Medicine 1994;155:2545-57.
14. Franzen D. Clinical efficacy of pneumococcal vaccination: a prospective study in patients with longstanding emphysema and/or bronchitis. European Journal of Medical Research 2000;5:537-40.
15. Gasparini R. L'influenza ed il suo impatto xulla salute. Sanità pubblica e medicina pratica 1999;5:11-4.
16. Gasparini R, Lucioni C, et al. Pharmacoeconomic issues in vaccine. Adis 2002;1-10.
17. Gluck R, Mischler R, Finkel B, Que JU, Scarpa B, Cryz SJ Jr. Immunogenicity of new virosome influenza vaccine in elderly people. Lancet 1994;344:160-3.
18. Grilli G, Fuiano L, Biasio LR, Pregliasco F, Plebani A, Leibovitz M, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. European Journal of Epidemiology April 1997;13:287-91.
19. Hogg G, Strachan JE, Lester RA. Invasive pneumococcal disease in the population of Victoria. MJA 2000;173:32-4.
20. Honkanen PO, Keistinen T, Kivela S. Reactions following administration of influenza vaccine alone or with pneumococcal vaccine to the elderly. Archives of Internal Medicine 1996;156:205-8.
21. Honkanen PO, Keistinen T, Miettinen L, Herva E, Sankilampi U, Laara E, et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999;17:2493-500.
22. Lasky T, Terracciano GJ, Magder L, Koski CL, Ballesteros M, Nash D, et al. The Guillan-Barrè syndrome and the 1992-1993 and 1993-1994 influenza vaccines. NEJM 1998;339:1797-802.
23. Lehmann D. Efficacy and effectiveness of pneumococcal polysaccharide vaccines and their use in industrialised countries. Medical Journal of Australia 2000;173:41-4.
24. McCashland TM, Preheim IC, Gentry-Nielson MJ. Pneumoccocal vaccine responses in cirrhosis and liver transplantation. J Infect Dis 2000;181:757-60.
25. Minutello M, Senatore F, Cecchinelli G, Bianchi M, Andreani T, Podda A, et al. Safety and immunogenicity of inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza season. Vaccine 1999;17:99-104.
26. Monto AS, Terpenning MS. The value of influenza and pneumococcal vaccines in the elderly. Drugs&Aging 1996;8:445-51.
27. Nichol KL, Baken L, Wuorenma J, Nelson A. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med 1999;159:2437-42.
28. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. NEJM 1994;331:778-84.
29. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992;7:26-37.
30. Ortqvist A, Hedlund J, Burman LA, Elbel E, Hofer M, Leinonen M, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 1998;351:399-403.
31. Pregliasco F. Vaccina antinfluenzale adiuvato virosomale. Focus 2002;5-35.
32. Pregliasco F, Donatelli I. L'influenza nell'anziano: impatto sanitaria e prevenzione. Geriatric and Medical Intelligence 2003;1:1-8.
33. Robbins JB, Austrian R, Lee CJ, Rastogi SC, Schiffman G, Henrichsen J, et al. Consideration for formulating the second-generation pneumococcal capsular polysaccharide vaccine with emphasis on the cross-reactive types within groups. J Infect Dis 1983;148:36-1159.
34. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, et al. Reduction in functional antibody activity against S. pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999;29:281-8.
35. Rothbarth PH, Kempen BM, Sprenger MJ. Sense and nonsense of influenza vaccination in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151:1682-5.
36. Rubins JB, Janoff EN. Pneumococcal disease in the elderly: what is preventing vaccine efficacy? Drugs&Aging 2001;18:305-11.
37. Santibanez TA, Nowalk MP, et al. Knowledge and beliefs about influenza, pneumococcal disease and immunizations among older people. J Am Geriatr Soc 2002;50:1711-6.
38. Santibanez TA, Nowalk MP, Zimmerman RK, Jewell IK, Bardella IJ, Wilson SA, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
39. Sims RV, Steinmann WC, McConville JH, King LR, Zwick WC, Schwartz JS. The clinical effectiveness of pneumococcal vaccine in the elderly. Ann Intern Med 1988;108:653-7.
40. Smit P, Oberholzer D, Hayden-Smith S, Koornhof HJ, Hilleman MR. Protective efficacy of pneumococcal polysaccharide vaccines. JAMA 1977;238:2613-6.
41. The Immunization Practices Advisory Committee. Prevention and control of influenza. MMWR Morb Mortal Wkly Rep 2002;51:1-13.
42. The Immunization Practise Advisory Committee. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 2003;52:1-2.
43. Vu T, Parish S, Jenkins M, Kelly H. A meta analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 2001;20:1831-6.
44. van Essen GA, Kuyvenhoven MM, de Melker RA, et al. Why do healthy elderly people fail to comply with influenza vaccination? Age and ageing 1997;26:275-9.
45. Weaver M, Krieger J, Castorina J, Walls M, Ciske S, et al. Cost-effectiveness of combined outreach for the pneumococcal and influenza vaccines. Arch Intern Med 2001;161:111-20.
46. Webster RG, Laver WG, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature 1982;296:115-21.
47. WHO. Influenza vaccines WHO position paper. WER 2002;77:229-40.
48. Williams JH, Moser KM. Pneumococcal vaccine and patients with chronic lung disease. Ann Intern Med 1986;104:106-9.
49. Whitney CG, Schaffner W, Butler JC. Rethinking recommendations for use of pneumococcal vaccines in adults. Vaccines 2001;33:662-75.